Metabolic effects of a growth hormone-releasing factor in patients with HIV.

@article{Falutz2007MetabolicEO,
  title={Metabolic effects of a growth hormone-releasing factor in patients with HIV.},
  author={Julian M Falutz and Soraya Allas and Koenraad H Blot and Diane Potvin and Donald P. Kotler and Michael S Somero and Daniel S Berger and Stephen Brown and Gary J. Richmond and Jeffrey Fessel and Ralph Turner and Steven K Grinspoon},
  journal={The New England journal of medicine},
  year={2007},
  volume={357 23},
  pages={
          2359-70
        }
}
BACKGROUND Visceral adipose tissue accumulates during antiretroviral therapy in many patients who are infected with the human immunodeficiency virus (HIV); this process is associated with an increased cardiovascular risk. We assessed the use of a growth hormone-releasing factor analogue, tesamorelin, to decrease visceral adiposity. METHODS We randomly assigned 412 patients with HIV (86% of whom were men) who had an accumulation of abdominal fat to receive a daily subcutaneous injection of… 

Figures and Tables from this paper

Predictors of Treatment Response to Tesamorelin, a Growth Hormone-Releasing Factor Analog, in HIV-Infected Patients with Excess Abdominal Fat
TLDR
Individuals with baseline MetS-NCEP, elevated triglyceride levels, or white race were most likely to experience reductions in VAT after 6 months of tesamorelin treatment, and Metabolic syndrome (MetS-IDF or MetS NCEP) and FRS were significantly associated with VAT at baseline.
Low-dose physiological growth hormone in patients with HIV and abdominal fat accumulation: a randomized controlled trial.
TLDR
In HIV-associated abdominal fat accumulation and relative GH deficiency, low-dose GH received for 18 months resulted in significantly reduced visceral fat and truncal obesity, triglycerides, and diastolic BP, but 2-hour glucose levels on glucose tolerance testing were increased.
Does low-dose growth hormone therapy improve the body composition of patients infected with HIV?
TLDR
It is found that administration of low-dose GH led to improvements in body composition (e.g. visceral adipose-tissue area), diastolic blood pressure and triglyceride levels, and this treatment regimen was not associated with an increased incidence of adverse events compared with placebo.
Management of Fat Accumulation in Patients with HIV Infection
  • J. Falutz
  • Medicine, Biology
    Current HIV/AIDS reports
  • 2011
TLDR
Effective long-term interventions to decrease central adiposity are limited but studies using growth hormone and especially growth hormone–releasing factor have shown encouraging results.
A characterisation of low-grade inflammation and metabolic complications in HIV-infected patients.
TLDR
It is proposed that both chronic low-grade inflammation from HIV infection and treatment with HAART trigger cellular homeostatic stress responses with adverse effects on glucose metabolism, which leads to a vicious circle of insulin resistance and lipotoxicity leading to lipoatrophy.
Effects of tesamorelin on inflammatory markers in HIV patients with excess abdominal fat: relationship with visceral adipose reduction
TLDR
In HIV patients with abdominal adiposity, tesamorelin may have a modest beneficial effect on adiponectin and fibrinolytic markers in association with changes in VAT, and these associations remained significant when controlling for changes in insulin-like growth factor-1.
Reduction in visceral adiposity is associated with an improved metabolic profile in HIV-infected patients receiving tesamorelin.
  • T. Stanley, J. Falutz, S. Grinspoon
  • Medicine
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2012
TLDR
In contrast to nonresponders, HIV-infected patients receiving tesamorelin with ≥8% reduction in VAT have significantly improved triglyceride levels, adiponectin levels, and preservation of glucose homeostasis over 52 weeks of treatment.
Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial.
TLDR
In this preliminary study of HIV-infected patients with abdominal fat accumulation, tesamorelin administered for 6 months was associated with reductions in visceral fat and additionally with modest reductions in liver fat.
The Effect of Recombinant Human Growth Hormone with or without Rosiglitazone on Hepatic Fat Content in HIV-1-Infected Individuals: A Randomized Clinical Trial
TLDR
Hematic fat correlates significantly with both VAT and IR, but changes in hepatic fat do not correlate with changes in VAT and glucose metabolism, suggesting an independent effect of GH or IGF-1 on hepaticfat.
Metabolic effects of a growth hormone-releasing factor in obese subjects with reduced growth hormone secretion: a randomized controlled trial.
TLDR
Among obese subjects with relative reductions in GH, tesamorelin selectively reduces VAT without significant effects on sc adipose tissue and improves triglycerides, C-reactive protein, and cIMT, without aggravating glucose.
...
...

References

SHOWING 1-10 OF 46 REFERENCES
A placebo-controlled, dose-ranging study of a growth hormone releasing factor in HIV-infected patients with abdominal fat accumulation
TLDR
TH9507 reduced truncal fat, improved the lipid profile and did not increase glucose levels in HIV-infected patients with central fat accumulation and longer-term studies with more patients are needed to determine effects on VAT, treatment durability, and safety.
Growth hormone-releasing hormone in HIV-infected men with lipodystrophy: a randomized controlled trial.
TLDR
GHRH was well tolerated and effectively increased levels of IGF-1 in HIV-infected men with lipodystrophy and total and regional body composition improved in response to GHRH, with increased lean mass and reduced truncal and visceral fat.
Effects of Growth Hormone on Abnormal Visceral Adipose Tissue Accumulation and Dyslipidemia in HIV-Infected Patients
TLDR
R-hGH dosed at 4 mg daily for 12 weeks decreases VAT and cholesterol concentrations in HIV-infected patients with excess VAT and the optimal regimen to sustain these effects awaits determination.
Recombinant human growth hormone to treat HIV-associated adipose redistribution syndrome: 12 week induction and 24-week maintenance therapy.
TLDR
In patients with HARS, r-hGH induction-maintenance therapy produces greater relative losses of VAT and trunk fat than of subcutaneous fat and also has beneficial effects on the lipid profile.
Recombinant Human Growth Hormone in Patients with HIV-Associated Wasting
TLDR
A randomized, multicenter, double-blind, placebo-controlled study that assessed the effects of growth hormone therapy on weight, body composition, functional performance, and quality of life in patients with HIV-associated wasting found that growth hormone may have a sustained effect on lean body mass.
Metformin in the treatment of HIV lipodystrophy syndrome: A randomized controlled trial.
TLDR
This study suggests that a relatively low dosage of metformin reduces insulin resistance and related cardiovascular risk parameters in HIV-infected patients with lipodystrophy.
Absence of an Effect of Liposuction on Insulin Action and Risk Factors for Coronary Heart Disease
TLDR
Liposuction decreased the volume of subcutaneous abdominal adipose tissue by 44 percent in the subjects with normal glucose tolerance and 28 percent in those with diabetes; those with normal oral glucose tolerance lost 9.1±3.7 kg of fat.
Fat distribution in HIV-infected patients reporting truncal enlargement quantified by whole-body magnetic resonance imaging.
TLDR
There was significantly more visceral adipose tissue in the subgroup of HIV-infected patients with truncal enlargement than in those without this sign, and VAS occurs in both men and women, is associated with higher CD4+ lymphocyte counts and lower plasma HIV viral burdens, and is not limited to those receiving protease inhibitors.
Comparison of Rosiglitazone and Metformin for Treating HIV Lipodystrophy
TLDR
A randomized study to compare the effects of rosiglitazone and metformin on insulin sensitivity, body fat distribution, and endothelial function in patients with HIV lipodystrophy among 39 HIV-infected men between 18 and 70 years of age.
Metabolic abnormalities and cardiovascular disease risk factors in adults with human immunodeficiency virus infection and lipodystrophy.
  • C. Hadigan, J. Meigs, S. Grinspoon
  • Medicine, Biology
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2001
TLDR
HIV-infected patients with lipodystrophy demonstrated significantly increased waist-to-hip ratios, fasting insulin levels, and diastolic blood pressure compared with controls, demonstrating a metabolic syndrome characterized by profound insulin resistance and hyperlipidemia.
...
...